TECH One billion doses of COVID-19 vaccines possible next year: CNBG

TECH

One billion doses of COVID-19 vaccines possible next year: CNBG

chinadaily.com.cn

17:35, December 14, 2020

A COVID-19 vaccine by China National Biotec Group Co. is displayed during the China International Fair for Trade in Services in Beijing on September 6. (File photo: VCG)

China National Biotec Group will have the capacity to produce 1 billion doses of COVID-19 vaccines next year, said the president of the group, Chinanews reported.

CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has been recognized as a comprehensive biopharmaceutical enterprise focusing on human vaccines, blood products, medical aesthetics and animal healthcare.

The company's two inactivated vaccine candidates are currently in phase III clinical trials in 10 countries and regions, with nearly 60,000 volunteers enrolled in the program, according to Yang Xiaoming, president of CNBG.

As of Nov 26, a total of 48 COVID-19 vaccine candidates have entered clinical trials worldwide, among which 11 have entered phase III clinical trials, he added. In China, four vaccine candidates are currently in phase III clinical trials, including three inactivated vaccines and one virus-carrier vaccine.

"It has been proved that the serum of the people vaccinated with the COVID-19 vaccines developed by CNBG provides cross-neutralization protection against multiple international epidemic strains, indicating the vaccines can play a protective role against novel coronavirus infection in many parts of the world," Yang said.

At present, CNBG's two workshops in Beijing and Wuhan have a combined production capacity of 300 million doses of vaccine per year.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue